

June 13, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Receipt of Establishment Inspection Report (EIR) by United States Food & Drug Administration (USFDA)

Ref: Our earlier intimation - Syn/CS/SE/Reg 30/2024-25/Feb/07

Further to our intimation dated February 21, 2025, regarding the inspection conducted by the United States Food & Drug Administration (USFDA) from February 10, 2025, to February 20, 2025, in connection with the routine current Good Manufacturing Practices (cGMP) inspection at our GMP manufacturing facilities located at Biocon Park, SEZ, Bengaluru. We hereby inform you that Company has received Establishment Inspection Report (EIR) from USFDA vide its communication dated June 11, 2025. The EIR concluded the inspectional outcome as **Voluntary Action Indicated (VAI)**. The US FDA has reviewed and accepted Syngene's responses and Corrective and Preventive Action (CAPA) plans submitted in response to the inspectional findings.

Syngene will continue to provide periodic updates to the USFDA on the progress of corrective actions submitted to the agency. We remain committed to maintaining the highest standards of regulatory compliance and this outcome will not have any adverse impact on the Company's financials or operations.

We request you to kindly take the same on record.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Chethan Yogesh
Head - Company Secretarial